London
· Delayed Price · Currency is GBP · Price in GBXArecor Therapeutics Statistics
Total Valuation
Arecor Therapeutics has a market cap or net worth of GBP 29.26 million. The enterprise value is 22.85 million.
| Market Cap | 29.26M |
| Enterprise Value | 22.85M |
Important Dates
The next estimated earnings date is Monday, September 23, 2024.
| Earnings Date | Sep 23, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Arecor Therapeutics has 37.76 million shares outstanding. The number of shares has increased by 5.83% in one year.
| Shares Outstanding | 37.76M |
| Shares Change (YoY) | +5.83% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 7.95% |
| Owned by Institutions (%) | 37.79% |
| Float | 25.20M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.19 |
| PB Ratio | 2.49 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.67 |
| EV / Sales | 5.00 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -3.81 |
Financial Position
The company has a current ratio of 2.17, with a Debt / Equity ratio of 3.55.
| Current Ratio | 2.17 |
| Quick Ratio | 1.96 |
| Debt / Equity | 3.55 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.06 |
| Interest Coverage | -611.67 |
Financial Efficiency
Return on equity (ROE) is -63.41% and return on invested capital (ROIC) is -41.54%.
| Return on Equity (ROE) | -63.41% |
| Return on Assets (ROA) | -30.88% |
| Return on Capital (ROIC) | -41.54% |
| Revenue Per Employee | 91,460 |
| Profits Per Employee | -171,080 |
| Employee Count | 50 |
| Asset Turnover | 0.25 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -57.33% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -57.33% |
| 50-Day Moving Average | 93.97 |
| 200-Day Moving Average | 137.57 |
| Relative Strength Index (RSI) | 28.11 |
| Average Volume (20 Days) | 8,331 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Arecor Therapeutics had revenue of GBP 4.57 million and -8.55 million in losses. Loss per share was -0.28.
| Revenue | 4.57M |
| Gross Profit | 4.57M |
| Operating Income | -9.18M |
| Pretax Income | -8.90M |
| Net Income | -8.55M |
| EBITDA | -8.88M |
| EBIT | -9.18M |
| Loss Per Share | -0.28 |
Balance Sheet
The company has 6.75 million in cash and 338,000 in debt, giving a net cash position of 6.41 million or 0.17 per share.
| Cash & Cash Equivalents | 6.75M |
| Total Debt | 338,000 |
| Net Cash | 6.41M |
| Net Cash Per Share | 0.17 |
| Equity (Book Value) | 9.53M |
| Book Value Per Share | 0.31 |
| Working Capital | 6.02M |
Cash Flow
In the last 12 months, operating cash flow was -5.84 million and capital expenditures -151,000, giving a free cash flow of -5.99 million.
| Operating Cash Flow | -5.84M |
| Capital Expenditures | -151,000 |
| Free Cash Flow | -5.99M |
| FCF Per Share | -0.16 |
Margins
Gross margin is 100.00%, with operating and profit margins of -200.63% and -187.05%.
| Gross Margin | 100.00% |
| Operating Margin | -200.63% |
| Pretax Margin | -194.64% |
| Profit Margin | -187.05% |
| EBITDA Margin | -194.18% |
| EBIT Margin | -200.63% |
| FCF Margin | -131.03% |
Dividends & Yields
Arecor Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.83% |
| Shareholder Yield | -5.83% |
| Earnings Yield | -36.04% |
| FCF Yield | -20.48% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |